IN VITRO EVALUATION OF THE COMBİNATION OF CEFTOLOZANE/TAZOBACTAM AND COLISTIN IN INTENSIVE CARE UNIT–ASSOCIATED MULTIDRUG-RESISTANT ACINETOBACTER BAUMANNII INFECTIONS

Year 2026, Volume: 7 Issue: 1, 9 - 15, 24.02.2026

Sümeyye Akyüz , Mehmet Parlak

https://doi.org/10.56766/ntms.1795369

https://izlik.org/JA32FE28XS

Abstract

Objective: Multidrug-resistant Acinetobacter baumannii (MDR-AB), a major cause of nosocomial infections, poses a global threat, particularly in immunosuppressed patients. Increasing resistance rates necessitate alternative therapeutic strategies for MDR-AB infections. In this study, we investigated the in vitro interactions of colistin (C) and the novel β-lactam/β-lactamase inhibitor combination ceftolozane/tazobactam (C/T) against MDR-AB isolates using the E-test and checkerboard methods.
Methods: Thirty MDR-AB isolates obtained between January and June 2017 from intensive care unit (ICU) patients were included. Isolate identification was performed using the BD Phoenix 100 and VITEK MS systems. Routine antimicrobial susceptibility testing was conducted with the BD Phoenix 100 system, and results were interpreted according to EUCAST guidelines. In vitro interactions of the C/T–C combination were evaluated using the fractional inhibitory concentration (FIC) index. The agreement between the E-test and checkerboard methods was analyzed using simple agreement rates and Cohen’s kappa coefficient.
Results: Resistance rates among MDR-AB isolates were as follows: imipenem, meropenem, ciprofloxacin, and gentamicin 100%; amikacin 86.7%; trimethoprim/sulfamethoxazole 46.7%; and colistin 10%. According to FIC index results, no synergistic interaction was observed with the E-test, whereas the checkerboard method demonstrated synergy in two isolates (6.7%). Antagonistic interactions were detected in 20% of isolates by the E-test but were absent with the checkerboard method. The overall agreement between the two methods was 50%, with a Cohen’s kappa coefficient of 0.13, indicating poor agreement.
Conclusion: The intrinsic susceptibility of MDR-AB isolates to C/T alone was low; however, the minimum inhibitory concentrations (MICs) of C/T decreased in the presence of colistin. The detection of synergistic activity and the absence of antagonism with the checkerboard method suggest the potential of combining C/T with reduced doses of colistin to minimize toxicity. However, further validation in in vivo experimental models is needed to substantiate the clinical significance of the observed synergistic effect.

Keywords

Multidrug resistance Acinetobacter baumannii , Checkerboard , Ceftolozane/tazobactam , Colistin , Combination

Ethical Statement

The study was approved by the Ethics Committee of Van Yüzüncü Yıl University Faculty of Medicine (30 November 2016; decision 2016/123)

Supporting Institution

This study was supported by the Scientific Research Projects Coordination Unit of Van Yüzüncü Yıl University (Project Fund).

Project Number

Project No: TTU-2017-5704

Thanks

This study was supported by the Scientific Research Projects Coordination Unit of Van Yüzüncü Yıl University (Project Fund).

References

• 1. Shields RK, Paterson DL, Tamma PD. Navigating available treatment options for carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex infections. Clin Infect Dis 2023;76(Suppl 2):179-93.
• 2. Baleivanualala SC, Matanitobua S, Samisoni Y, et al. Environmental contamination with carbapenem resistant Acinetobacter baumannii in healthcare settings in Fiji: a potential source of infection. Front Cell Infect Microbiol 2024;14:1429443.
• 3. Shamsizadeh Z, Nikaeen M, Nasr Esfahani B, Mirhoseini SH, Hatamzadeh M, Hassanzadeh A. Detection of antibiotic resistant Acinetobacter baumannii in various hospital environments: potential sources for transmission of Acinetobacter infecti ons. Environ Health Prev Med 2017;22(1):44.
• 4. Reina R, León-Moya C, Garnacho-Montero J. Treatment of Acinetobacter baumannii severe infections. Med Intensiv 2022;46:700–10.
• 5. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious diseases society of america guidance on the treatment of AmpC β-lactamase-producing enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections. Clin Infect Dis 2022;74(12):2089–114.
• 6. Paul M, Carrara E, Retamar P, et al. European society of clinical microbiology and infectious diseases (ESCMID) guidelines for the treatment of infections caused by multidrug resistant Gram-negative bacilli (endorsed by European society of inten sive care medicine). Clin Microbiol Infect 2022;28(4):521–47.
• 7. Tan TY, Lim TP, Lee WHL, Sasikala S, Hsu LY, Kwa ALH. In vitro antibiotic synergy in extensively drug-resistant Acinetobacter baumannii: the effect of testing by time-kill, checkerboard, and Etest methods. Antimicrob Agents Chemother 2011;55(1):436-38.
• 8. Jiang Z, He X, Li J. Synergy effect of meropenem-based combinations against Acinetobacter baumannii: A systematic review and meta-analysis. Infect Drug Resist 2018;11:1083–95.
• 9. Elaldı N. Ufuktaki Yeni Antibiyotikler. Flora Derg 2015;20(1):1-9.
• 10. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical breakpoint tables. Acinetobacter spp. Version 7.1 (valid from 2017-08-02).
• 11. Hogg GM, Barr JG, Webb CH. In-vitro activity of the combination of colistin and rifampicin against multidrug-resistant strains of Acinetobacter baumannii. J Antimicrob Chemother 1998;4:494-5.
• 12. Kyriakidis I, Vasileiou E, Pana ZD, Tragiannidis A. Acinetobacter baumannii Antibiotic Resistance Mechanisms. Pathogens 2021;10:373.
• 13. Gedefie A, Demsis W, Ashagrie M, et al. Acinetobacter baumannii Biofilm Formation and Its Role in Disease Pathogenesis:A Review. Infect. Drug Resist. 2021;14,3711-19.
• 14. Ozma MA, Abbasi A, Asgharzadeh M et al. Antibiotic Therapy for Pan-Drug Resistant Infections. Infez Med 2022;30:525-31.
• 15. Khalil MAF, Ahmed, FA, Elkhateeb AF, et al. Virulence Characteristics of Biofilm-Forming Acinetobacter baumannii in Clinical Isolates Using a Galleria Mellonella Model. Microorganisms 2021;9:2365.
• 16. Çeken N, Duran H, Kula Atik T. Distribution of gram negative bacteria isolated from blood culture and antibiotic resistance rates. Turk Bull Hyg Exp Biol 2022;79(3):451-60.
• 17. Aytaç Ö, Öner P, Şenol FF, Aşçı-Toraman Z. Klinik Örneklerden İzole Edilen Çoklu Dirençli Acinetobacter baumannii İzolatlarının Kolistin Direncinin Sıvı Mikrodilüsyon, Sensititre ve İki Farklı Otomatize Sistem ile Karşılaştırılması. Klimik Journ 2022;35(3):159-63.
• 18. Liscio JL, Mahoney MV, Hirsch EB. Ceftolozane/tazobactam and Ceftazidime/avibactam: Two Novel β-lactam/β-lactamase Inhibitor Combination Agents for the Treatment of Resistant Gram-negative Bacterial Infections. Int J Antimicrob Agents 2015;46(3):266-71.
• 19. Hsueh SC, Lee YJ, Huang Y, Liao CH, Tsuji M, Hsueh PR. In vitro activities of cefiderocol, ceftolozane/ta zobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan. J Antimicrob Chemother 2019;74(2):380-6.
• 20. Dobias J, Dénervaud-Tendon V, Poirel L ve Nordmann P. Activity of the Novel Siderophore Cephalosporin Cefiderocol Against Multidrug-Resistant Gram-negative Pathogens. Eur J Clin Microbiol Infect Dis.2017;36(12):2319-27.
• 21. Sader HS, Farrell DJ, Flamm RK ve Jones RN. Ceftolozane/tazobactam Activity Tested Against Aerobic Gram-negative Organisms Isolated from Intra-abdominal and Urinary Tract Infections in European and United States Hospitals (2012). J Infect. 2014;69(3):266-77.
• 22. Ku NS, Lee SH, Lim YS et al. In vivo efficacy of combination of colistin with fosfomycin or minocycline in a mouse model of multidrug-resistant Acinetobacter baumannii pneumonia. Sci Rep 2019;9(1):17127.
• 23. Boncompagni SR, Micieli M, Di Maggio T, et al. Activity of fosfomycin/colistin combinations against plank tonic and biofilm gram-negative pathogens. J Antimicrob Chemother 2022;77(8):2199–208.
• 24. Ju YG, Lee HJ, Yim HS, Lee MG, Sohn JW, Yoon YK. In vitro synergistic antimicrobial activity of a combination of meropenem, colistin, tigecycline, rifampin, and ceftolozane/tazobactam against carbapenem-resistant Acinetobacter baumannii. Sci Rep 2022;12(1):7541.
• 25. Jacqueline C, Howland K ve Chesnel L. In vitro Activity of Ceftolozane/tazobactam in Combination with Other Classes of Antibacterial Agents. J Glob Antimicrob Resist 2017;10:326-29.
• 26. Smith JR, Arya A, Yim J, et al.. Daptomycin in Combination with Ceftolozane-tazobactam or Cefazolin Against Daptomycin-Susceptible and-Nonsusceptible Staphylococcus aureus in an In vitro, Hollow-Fiber Model. Antimicrob Agents Chemother 2016;60(7):3970-75.
• 27. Jiang Z, He X, Li J. Synergy effect of meropenem-based combinations against Acinetobacter baumannii: a systematic review and meta-analysis. Infect Drug Resist 2018;11:1083–95.
• 28. Zarakolu P, Ayaz ÇM, Metan G. Karbapeneme dirençli Acinetobacter baumannii enfeksiyonlarının tedavisinde kullanılan çeşitli antibiyotik kombinasyonları ve in vitro sinerji test sonuçları (2002-2016). Mikrobiyol Bul 2018;52(2):190–7.